Abstracts tagged "interleukins (IL)"

Abstract Number: 1440 • 2013 ACR/ARHP Annual Meeting
Effects Of Tocilizumab On Serum Cytokines In Rheumatoid Arthritis With An Inadequate Response To Disease-Modifying Antirheumatic Drugs
Sang Jin Lee^1,2, Kyung Rok Kim³, Sang Hyun Joo³, Jae Myung Lee³, In Ah Choi³, Joo Youn Lee², Hyun Jung Yoo², Eun Young Lee⁴, Eun Bong Lee¹, Won Park⁵, Sung Hwan Park⁶, Seung-Cheol Shim⁷, Dae-Hyun Yoo⁸, Han Joo Baek⁹, Hyun Ah Kim¹⁰, Soo Kon Lee¹¹, Yun Jong Lee¹, Young Eun Park¹², Hoon-Suk Cha¹³ and Yeong Wook Song^2,3, ¹Division of Rheumatology, Department of Internal Medicine, Rheumatology, Seoul National University, Seoul, South Korea, ²Department of molecular medicine and biophamaceutical sciences,Seoul National University, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ⁴Internal medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Rheumatology, The Catholic University, Seoul, South Korea, ⁷Medicine, Rheumatology, Eulji University, Daejeon, South Korea, ⁸Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁹Rheumatology, Rheumatology, Gachon University, Incheon, South Korea, ¹⁰Division of Rheumatology, Department of Internal Medicine, Hallym university, Kyunggi, South Korea, ¹¹Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ¹²Rheumatology, Rheumatology, Pusan Nationl University, Pusan, South Korea, ¹³Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: The objective of this study was to investigate the effects of tocilizumab on serum cytokines in rheumatoid arthritis (RA) patients with an inadequate response…
Abstract Number: 1375 • 2013 ACR/ARHP Annual Meeting
Synergistic Enhancement Of Aggregated IgG-Induced Tumor Necrosis Factor α In Human Synovial Mast Cells By Interleukin 33
Hyunho Lee^1,2, Jun-ichi Kashiwakura³, Masahiko Yanagisawa^1,2, Yuki Okamura^1,2, Takao Ishii², Masayuki Seki², Shu Saito², Yasuaki Tokuhashi², Chisei Ra¹ and Yoshimichi Okayama¹, ¹Allergy and Immunology Group, Nihon University School of Medicine, Tokyo, Japan, ²Department of Orthopaedic Surgery, Nihon University School of Medicine, Tokyo, Japan, ³Laboratory for Allergic Disease, RIKEN Center for Integrateive Medical Sciences, Kanagawa, Japan
Background/Purpose: Recent studies suggest that human synovial mast cells (MCs) are involved in the pathogenesis of rheumatoid arthritis (RA). Circulating IgG isotype autoantibodies and synovial…
Abstract Number: 152 • 2012 ACR/ARHP Annual Meeting
Rilonacept for Gout Flare Reduction: Estimation of Number Needed to Treat to Benefit (NNTB)
Robert R. Evans¹, Steven P. Weinstein², George D. Yancopoulos³ and Yuhwen Soo⁴, ¹Clinical Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ²Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ³Research Labs, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Two similarly designed phase 3 randomized clinical trials (PRESURGE-1 and PRESURGE-2) in gout patients initiating urate-lowering therapy (ULT) showed that subcutaneous treatment with the…
Abstract Number: 1178 • 2012 ACR/ARHP Annual Meeting
IL-6 and IL-21 in Rheumatoid Arthritis
Gustavo Carbone¹, Augusta Wilson¹, Sean Diehl², Janice Bunn³, Sheldon Cooper⁴ and Mercedes Rincon⁵, ¹Rheum & Clinical Imm Unit, University of Vermont College of Medicine, Burlington, VT, ²Immunobiology, University of Vermont College of Medicine, ³Mathematics and Statistics, University of Vermont, Burlington, VT, ⁴Rheum & Clinical Imm Unit, Univ Vermont College of Med, Burlington, VT, ⁵Immunobiology, University of Vermont College of Medicine, Burlington, VT
Background/Purpose: Interleukin-6 (IL-6) levels are known to be increased in patients with rheumatoid arthritis (RA). Tocilizumab, a monoclonal antibody to the IL-6 receptor (IL-6R), reduces…
Abstract Number: 2119 • 2012 ACR/ARHP Annual Meeting
Interleukin-6 As a Biomarker for the Clinical and Radiological Effectiveness of Methotrexate in Rheumatoid Arthritis
Naoshi Nishina, Hideto Kameda, Yuko Kaneko, Masataka Kuwana and Tsutomu Takeuchi, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Methotrexate (MTX) is now an anchor drug in the treatment strategy of rheumatoid arthritis (RA) and its effectiveness has been established. However it is…
Abstract Number: 21 • 2012 ACR/ARHP Annual Meeting
IL-32 and IL-17 Interact and Aggravate Osteoclastogenesis in Rheumatoid Arthritis
Bo Young Yoon¹, Young-Mee Moon², Yang-Mi Her², Hye Jwa Oh², Jae-Seon Lee², Kyoung-Woon Kim³, Seon-Yeong Lee², Yun-Ju Woo², Kyung-Su Park², Sung-Hwan Park⁴, Ho-Youn Kim² and Mi-La Cho², ¹Inje University Ilsan Paik Hospital, Goyang, South Korea, ²Rheumatism Research Center, Catholic Research Institute of Medical Science, Catholic University of Korea, Seoul, South Korea, ³Conversant Research Consortium in Immunologic disease, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, ⁴Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea
Background/Purpose: Interleukin (IL)-32 and IL-17 play critical roles in pro-inflammatory responses and are highly expressed in the synovium of patients with rheumatoid arthritis (RA). We…
Abstract Number: 1209 • 2012 ACR/ARHP Annual Meeting
Functional Role of Chondrogenic Progenitor Cells in Rheumatoid Arthritis
Sabine Blaschke¹, Sandra Trautmann¹, Alexander W. Beham², Burkhard Mai³, Sebastian Koelling¹, Caroline Breysach⁴, Gabriele Wolf¹, Gerhard A. Mueller¹ and Nicolai Miosge⁵, ¹Nephrology & Rheumatology, University Medical Center Goettingen, Goettingen, Germany, ²Department of Surgery, Germany, ³Vitos Orthopaedic Clinic Kassel, Kassel, Germany, ⁴Department of Surgery, Goettingen, Germany, ⁵Dept. of Prosthodontics, Goettingen, Germany
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease of still unknown etiology leading to progressive cartilage and bone destruction. Proinflammatory cytokines, immunoregulatory cells…
Abstract Number: 2293 • 2012 ACR/ARHP Annual Meeting
Interleukin-17A Positive Cells Are Increased in Systemic Sclerosis Skin and Their Number Is Inversely Correlated to Skin Thickness
Marie-Elise Truchetet¹, Nicolò Costantino Brembilla¹, Elisa Montanari¹, Paola Lonati², Pier Luigi Meroni³ and Carlo Chizzolini¹, ¹University hospital of Geneva, Geneva, Switzerland, ²Division of Rheumatology, Istituto G. Pini, University of Milan, Milan, Italy, ³Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy
Background/Purpose: T cell producing IL-17A are increased in the peripheral blood of individuals affected by systemic sclerosis (SSc). We asked the question whether IL-17A-producing cells…
Abstract Number: 316 • 2012 ACR/ARHP Annual Meeting
The Interleukin-10 (IL-10) Producing Regulatory B Cell (“B10 cell”) Compartment Expands with Disease Activity in Juvenile Dermatomyositis (JDM) and Pediatric-Onset Systemic Lupus Erythematosus (pSLE)
Ioannis Kalampokis¹, Jeffrey A. Dvergsten² and Thomas Tedder³, ¹Immunology and Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ²Pediatrics Division of Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ³Department of Immunology, Duke University Medical Center, Durham, NC
Background/Purpose: pSLE and JDM are multisystem inflammatory diseases, whereas juvenile idiopathic arthritis (JIA) is typically an organ-limited disease. “B10 cells”, a rare subset of human…
Abstract Number: 1279 • 2012 ACR/ARHP Annual Meeting
First in Human Study with Recombinant Anti-IL-21 Monoclonal Antibody in Healthy Subjects and Patients with Rheumatoid Arthritis
Stanislav Ignatenko¹, Birte K. Skrumsager², Adam Steensberg³ and Ulrik Mouritzen³, ¹Charité Research Organization GmbH, Berlin, Germany, ²Clinical Pharmacology Biopharm, Novo Nordisk A/S, Copenhagen, Denmark, ³Medical & Science, Inflammation, Novo Nordisk A/S, Copenhagen, Denmark
Background/Purpose: Interleukin-21 (IL-21), a cytokine produced by activated T cells (especially T17 and TFH cells), has a proinflammatory and pleiotropic nature, and drives mainly activation…
Abstract Number: 2329 • 2012 ACR/ARHP Annual Meeting
Increase of CD4⁺CD25⁺FoxP₃⁺ T Cell in Patients with Systemic Sclerosis Could Secret IL-17 with Dysfunction of Immunosuppression
Xinjuan Liu¹, Na Gao¹, Mengtao Li¹, Dong Xu¹, Yong Hou¹, Qian Wang¹, Guohua Zhang¹, Qiuning Sun², Henghui Zhang³ and Xiaofeng Zeng⁴, ¹Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ²Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ³Hepatology Institute, Peking University, People's Hospital, Beijing, China, ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Background/Purpose: Immune unbalance between Th17 and regulatory T cells (Treg) is a characteristic of systemic sclerosis (SSc). The functional heterogeneity and differentiation dynamics can be…
Abstract Number: 310 • 2012 ACR/ARHP Annual Meeting
STAT3 Plays a Central Role in NLRP3 Inflammasome-Mediated IL-1β Production and Pyronecrosis
Jehad H. Edwan¹, Tri M. Tran², Mones Abu-Asab³, Raphaela T. Goldbach-Mansky⁴ and Robert A. Colbert¹, ¹NIAMS NIH, Bethesda, MD, ²NIAMS/NIH, Bethesda, MD, ³NEI NIH, Bethesda, MD, ⁴Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD
Background/Purpose: Gain of function mutations in NLRP3 cause cryopyrin-associated periodic fever syndromes (CAPS), the most severe form of which is neonatal-onset multisystem inflammatory disease (NOMID),…
Abstract Number: 1307 • 2012 ACR/ARHP Annual Meeting
Anti-IL-6 Receptor Nanobody (ALX-0061) Seamless “First-in-Human” Phase I/II POC Study in Patients with Active RA On Stable MTX Treatment
Steven De Bruyn¹, Béla Gachályi², Bernadette Rojkovich³, Slavomir Bruk⁴, Petr Sramek⁵, Mariusz Korkosz⁶, Krzysztof Krause⁷, Pieter Schoen⁸, Laura Sargentini-Maier⁹, Joke D'Artois¹⁰, Katrien Verschueren¹⁰, Katelijne De Swert¹⁰, Gerhard Arold¹¹ and Josefin-Beate Holz¹², ¹Clinical Development, Ablynx N.V., Zwijnaarde, Belgium, ²Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Péterfy Sándor Utcai Kórház, Budapest, Hungary, ³II. sz. Reumatológiai Osztály, Budai Irgalmasrendi Kórház Kht., Budapest, Hungary, ⁴Interni oddeleni, Nemocnice Trinec, Trinec, Czech Republic, ⁵Pharmaceutical Research Associates CZ, Praha, Czech Republic, ⁶Malopolskie Centrum Medyczne, Krakow, Poland, ⁷Specjalistyczny im. J. Gromkowskiego, Wojewodzki Szpital, Wroclaw, Poland, ⁸Project Management, Ablynx N.V., Zwijnaarde, Belgium, ⁹Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ¹⁰Clinical Development, Ablynx nv, Zwijnaarde, Belgium, ¹¹Medical Affairs, PRA International GmbH, Berlin, Germany, ¹²Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose: ALX-0061 is a 26kD bispecific IL-6R targeting Nanobody® with monovalent binding to IL-6R and serum albumin. It effectively neutralizes IL-6 pathway activity in-vitro and…
Abstract Number: 2372 • 2012 ACR/ARHP Annual Meeting
Efficacy of Quantitative Analysis of Brainstem Atrophy On Magnetic Resonance Imaging for Diagnosis of Chronic Progressive Neuro-Behçet’s Disease
Hirotoshi Kikuchi¹, Maki Takayama², Yoshitaka Kimura², Kurumi Asako², Hajime Kono², Yasuo Ono¹ and Shunsei Hirohata³, ¹Department of Microbiology and Immunology, Teikyo University Shool of Medicine, Tokyo, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose : CNS involvement in Behçet's disease, usually called neuro-Behçet's disease (NB), can be classified into acute NB (ANB) and chronic progressive NB (CPNB) based…
Abstract Number: 336 • 2012 ACR/ARHP Annual Meeting
Preclinical Development of ALX-0061, an Anti-IL-6R Nanobody^®For Therapeutic Use in Rheumatoid Arthritis with a High in Vitro Affinity and Potency and a Competitive in Vivo Pharmacological Profile
Maarten Van Roy¹, Hans Ulrichts², Stefaan Rossenu², Sandy Jacobs², Sofie Poelmans³, Gert Verheyden², Michel Vierboom⁴, Bert 't Hart⁴, Judith Baumeister¹ and Josefin-Beate Holz⁵, ¹Department of Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ²Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ³Pharmacology, Ablynx NV, Gent, Belgium, ⁴Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, Netherlands, ⁵Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose: Interleukin-6 (IL-6) is a pleiotropic cytokine inducing a wide range of biological activities via its receptor IL-6R. IL-6 plays an important role in the…